300122 智飞生物
已收盘 01-14 15:00:00
资讯
新帖
简况
智飞生物最新公告：预计2025年归母净亏损106.98亿元-137.26亿元
证券之星 · 01-13 07:31
智飞生物最新公告：预计2025年归母净亏损106.98亿元-137.26亿元
智飞生物(300122.SZ)：CA111注射液进入Ⅰ期临床试验
智通财经 · 01-12 19:01
智飞生物(300122.SZ)：CA111注射液进入Ⅰ期临床试验
股市必读：智飞生物（300122）1月9日董秘有最新回复
证券之星 · 01-12
股市必读：智飞生物（300122）1月9日董秘有最新回复
智飞生物：关于公司控股股东部分股份解除质押的公告（2026-03）
证券之星 · 01-09
智飞生物：关于公司控股股东部分股份解除质押的公告（2026-03）
疫苗龙头智飞生物存货200亿，借102亿续命，今年大批九价HPV疫苗将过期
21世纪经济报道 · 01-09
疫苗龙头智飞生物存货200亿，借102亿续命，今年大批九价HPV疫苗将过期
智飞生物实控人蒋仁生解押6545万股 累计质押10%持股
中金财经 · 01-06
智飞生物实控人蒋仁生解押6545万股 累计质押10%持股
股市必读：智飞生物（300122）12月31日董秘有最新回复
证券之星 · 01-05
股市必读：智飞生物（300122）12月31日董秘有最新回复
每周股票复盘：智飞生物（300122）德谷门冬双胰岛素注射液获Ⅲ期临床总结报告
证券之星 · 01-03
每周股票复盘：智飞生物（300122）德谷门冬双胰岛素注射液获Ⅲ期临床总结报告
智飞生物：截至2025年12月19日股东人数为124,518
证券之星 · 2025-12-31
智飞生物：截至2025年12月19日股东人数为124,518
智飞生物德谷门冬双胰岛素注射液完成III期临床试验，有效性及安全性与原研药相当
中金财经 · 2025-12-29
智飞生物德谷门冬双胰岛素注射液完成III期临床试验，有效性及安全性与原研药相当
深市“双提升”：471家率先行动，分红占净利润比重2年提升近11个百分点
第一财经 · 2025-12-27
深市“双提升”：471家率先行动，分红占净利润比重2年提升近11个百分点
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理
智通财经 · 2025-12-17
智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理
12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 2025-12-11
12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股
12月4日智飞生物现1笔大宗交易 机构净买入399.2万元
证券之星 · 2025-12-04
12月4日智飞生物现1笔大宗交易 机构净买入399.2万元
智飞生物：截至2025年11月20日股东人数为130,074
证券之星 · 2025-11-28
智飞生物：截至2025年11月20日股东人数为130,074
智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%
证券之星 · 2025-11-20
智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理
智通财经网 · 2025-11-19
智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理
智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%
证券之星 · 2025-11-19
智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%
股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%
证券之星 · 2025-11-17
股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%
智飞生物：四价流感疫苗已获批上市
证券之星 · 2025-11-14
智飞生物：四价流感疫苗已获批上市
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":20.03,"timestamp":1768374225000,"preClose":20.19,"halted":0,"volume":45418809,"delay":0,"changeRate":-0.0079,"floatShares":1414000000,"shares":2394000000,"eps":-0.5592,"marketStatus":"已收盘","change":-0.16,"latestTime":"01-14 15:00:00","open":19.96,"high":20.58,"low":19.8,"amount":918000000,"amplitude":0.0386,"askPrice":20.03,"askSize":509,"bidPrice":20.02,"bidSize":217,"shortable":0,"etf":0,"ttmEps":-0.5592,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768440600000},"marketStatusCode":5,"adr":0,"adjPreClose":20.19,"symbolType":"stock","openAndCloseTimeList":[[1768354200000,1768361400000],[1768366800000,1768374000000]],"highLimit":22.21,"lowLimit":18.17,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.65,"roa":"--","roe":"--","epsLYR":0.8427,"committee":-0.250936,"marketValue":47948000000,"turnoverRate":0.0321,"status":1,"floatMarketCap":28329000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2603852289","title":"智飞生物最新公告：预计2025年归母净亏损106.98亿元-137.26亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603852289","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603852289?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:31","pubTimestamp":1768260690,"startTime":"0","endTime":"0","summary":"智飞生物1月12日晚间公告，预计2025年归属于上市公司股东的净利润亏损1,069,793.61万元-1,372,565.38万元，比上年同期下降630%-780%，上年同期盈利201,847.85万元。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300005179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0196","LU2148510915.USD","BK0046","LU1328615791.USD","BK0188","BK0077","LU1064130708.USD","LU1064131003.USD","BK0239","LU2580892862.HKD","LU2580892789.USD"],"gpt_icon":0},{"id":"2602193675","title":"智飞生物(300122.SZ)：CA111注射液进入Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2602193675","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602193675?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由控股子公司重庆宸安生物制药有限公司研发的CA111注射液在浙江省开展Ⅰ期临床试验。宸安生物研制的CA111 注射液是一款葡萄糖依赖性胰岛素释放肽受体和胰高血糖素样肽-1受体的双重激动剂。GLP-1是37个氨基酸的肽，其刺激胰岛素分泌和保护胰腺β细胞，并抑制胰高血糖素分泌、胃排空和食物摄入，从而控制血糖和体重。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","BK0196","LU2580892789.USD","BK0188","BK0046","LU1064131003.USD","300122"],"gpt_icon":0},{"id":"2602552643","title":"股市必读：智飞生物（300122）1月9日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602552643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602552643?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:22","pubTimestamp":1768152129,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，智飞生物报收于19.8元，上涨1.69%，换手率1.81%，成交量25.53万手，成交额5.05亿元。董秘最新回复投资者： 请问截止12月31日公司股东人数是多少？董秘： 您好，公司2025年12月31日股东人数及其详情请关注并查阅公司定期报告披露的相关内容，感谢关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200000580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0188","BK0046","LU1064130708.USD","LU2580892789.USD","LU1328615791.USD","BK0077","LU1064131003.USD","300122","BK0239","BK0196","LU2580892862.HKD"],"gpt_icon":0},{"id":"2602323021","title":"智飞生物：关于公司控股股东部分股份解除质押的公告（2026-03）","url":"https://stock-news.laohu8.com/highlight/detail?id=2602323021","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602323021?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:25","pubTimestamp":1767947107,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物01月09日在投资者关系平台上答复投资者关心的问题。智飞生物回复：您好，关于公司控股股东部分股份解除质押的事项已于2026年1月5日披露于证监会指定的信息披露网站，详见《关于公司控股股东部分股份解除质押的公告》，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900023740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","BK0046","BK0196","300122","LU1064130708.USD","LU1328615791.USD","BK0077","BK0188","BK0239","LU2580892789.USD"],"gpt_icon":0},{"id":"2602341459","title":"疫苗龙头智飞生物存货200亿，借102亿续命，今年大批九价HPV疫苗将过期","url":"https://stock-news.laohu8.com/highlight/detail?id=2602341459","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602341459?lang=zh_cn&edition=full","pubTime":"2026-01-09 13:25","pubTimestamp":1767936300,"startTime":"0","endTime":"0","summary":" 2026年1月5日晚间，A股疫苗龙头智飞生物发布公告，拟申请总额不超过102亿元、期限最长3年的中长期贷款，用于置换存量融资及补充日常营运资金。 2025年三季度，智飞生物已陷入12亿元亏损，更严峻的是，其核心库存产品九价HPV疫苗保质期为3年，2026年将迎来大批疫苗过期节点，可能引发大规模坏账计提。 上述公告发布后，智飞生物股价略有回升，截至1月9日早盘，近5日涨近4%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2026-01-09/doc-inhfssrr3021094.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2026-01-09/doc-inhfssrr3021094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","300122","BK0239","BK0188","LU1328615791.USD","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","159646","159645","BK0077","LU2580892789.USD","BK0196","LU2580892862.HKD"],"gpt_icon":0},{"id":"2601869422","title":"智飞生物实控人蒋仁生解押6545万股 累计质押10%持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601869422","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601869422?lang=zh_cn&edition=full","pubTime":"2026-01-06 14:52","pubTimestamp":1767682331,"startTime":"0","endTime":"0","summary":"公司近日接到公司控股股东、实际控制人蒋仁生的通知，获悉蒋仁生所持有公司的部分股份解除质押。 蒋仁生本次解除质押股数为65,450,000股，占其所持股份比例5.64%，占公司总股本比例2.73%，解除日期为2025年12月30日，质权人为重庆农村商业银行股份有限公司。 截至公告披露日，公司控股股东、实际控制人蒋仁生持股数量1,159,573,500股，持股比例为48.44%，累计被质押股份数量为119,250,000股，合计占其所持股份比例10.28%，合计占公司总股本比例4.98%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202601/06/20260106258880.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202601/06/20260106258880.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260106/31918917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1064130708.USD","LU2580892789.USD","BK0046","BK0188","BK0077","LU1328615791.USD","300122","LU2148510915.USD","BK0239","LU2580892862.HKD","LU1064131003.USD","BK0196"],"gpt_icon":0},{"id":"2601262350","title":"股市必读：智飞生物（300122）12月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2601262350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601262350?lang=zh_cn&edition=full","pubTime":"2026-01-05 01:35","pubTimestamp":1767548112,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，智飞生物报收于18.87元，下跌0.58%，换手率0.7%，成交量9.93万手，成交额1.88亿元。董秘最新回复投资者： 董秘，您好！谢谢董秘： 您好，截至2025年12月19日，公司普通股股东人数为124,518，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","LU1328615791.USD","LU2580892789.USD","LU2148510915.USD","BK0077","BK0196","300122","BK0188","BK0046","LU2580892862.HKD","LU1064130708.USD"],"gpt_icon":0},{"id":"2600606294","title":"每周股票复盘：智飞生物（300122）德谷门冬双胰岛素注射液获Ⅲ期临床总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2600606294","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600606294?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:02","pubTimestamp":1767376935,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，智飞生物报收于18.87元，较上周的19.24元下跌1.92%。本周，智飞生物12月29日盘中最高价报19.28元。本周关注点公司公告汇总：德谷门冬双胰岛素注射液获得Ⅲ期临床试验总结报告。该药品用于治疗成人2型糖尿病，为治疗用生物制品。临床试验结果显示其有效性和安全性与原研药诺和佳相当，符合相关指导原则要求。目前该产品尚未上市，需提交注册申请并经审评审批，后续进展存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1064130708.USD","BK0196","BK0046","LU1328615791.USD","LU1064131003.USD","BK0077","300122","LU2148510915.USD","LU2580892862.HKD","LU2580892789.USD","BK0188"],"gpt_icon":0},{"id":"2595216722","title":"智飞生物：截至2025年12月19日股东人数为124,518","url":"https://stock-news.laohu8.com/highlight/detail?id=2595216722","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595216722?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:51","pubTimestamp":1767171074,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)12月31日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至12月20日公司的股东人数是多少？谢谢智飞生物回复：您好，截至2025年12月19日，公司普通股股东人数为124,518，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100029613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","LU1064130708.USD","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","BK0188","LU2580892862.HKD","300122","LU2148510915.USD","BK0077","BK0046"],"gpt_icon":0},{"id":"2595878686","title":"智飞生物德谷门冬双胰岛素注射液完成III期临床试验，有效性及安全性与原研药相当","url":"https://stock-news.laohu8.com/highlight/detail?id=2595878686","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595878686?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:34","pubTimestamp":1767000854,"startTime":"0","endTime":"0","summary":"中访网数据 重庆智飞生物制品股份有限公司于近日发布公告，宣布其控股子公司重庆宸安生物制药有限公司研发的德谷门冬双胰岛素注射液已获得III期临床试验总结报告。该药品适应症为治疗成人2型糖尿病。根据多中心、随机、开放、平行对照的临床试验结果，本品在有效性和安全性上与原研药德谷门冬双胰岛素注射液(诺和佳)相当，符合相关指导原则的要求。目前，除原研药外，国内有1家企业的同类产品已获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251229/31899920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","LU1064130708.USD","BK4134","LU2580892862.HKD","LU1064131003.USD","BK0196","BK0077","III","LU2148510915.USD","LU2580892789.USD","300122","BK0188","LU1328615791.USD","BK0046"],"gpt_icon":0},{"id":"2594521497","title":"深市“双提升”：471家率先行动，分红占净利润比重2年提升近11个百分点","url":"https://stock-news.laohu8.com/highlight/detail?id=2594521497","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594521497?lang=zh_cn&edition=full","pubTime":"2025-12-27 11:01","pubTimestamp":1766804460,"startTime":"0","endTime":"0","summary":" 已有471家深市公司披露行动方案。 去年2月，深交所正式启动“质量回报双提升”专项行动，旨在推动全体上市公司夯实发展质量、增强投资价值回报能力。 市场反应积极正面，2024年2月至2025年11月，471家“双提升”公司股价平均涨幅77.2%，高于深证成指涨幅。截至2025年11月底，市值合计21.2万亿元，较专项行动启动前增长8.1万亿元，占深市总市值比重50.0%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-27/doc-inheezwv0075071.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-27/doc-inheezwv0075071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0823426480.USD","LU0405327148.USD","LU1242518857.USD","LU2348774022.SGD","BK0046","300009","LU1508157978.USD","LU1655091616.SGD","002493","300760","BK0060","BK0196","002821","LU1969619763.USD","LU2495084118.USD","LU1861214812.USD","LU0594300419.USD","300122","BK0070","BK0132","LU0650527681.SGD","300919","BK0109","LU2580892789.USD","IE0008368742.USD","301095","300476","LU0633140727.USD","BK0251","LU2348773727.SGD","EVS.SI","LU2148510915.USD","LU2663582299.SGD","SGXZ49509284.SGD","LU0469268626.HKD","002594","BK0231","LU1997245094.SGD","LU1328615791.USD","002241","BK0197","000725","IE00B031J352.USD","IE00B29SXG58.USD","LU1734074674.USD","LU1064130708.USD","LU2153592121.USD","LU2289578879.USD","BK0188","BK0187"],"gpt_icon":0},{"id":"2592600029","title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592600029","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592600029?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:39","pubTimestamp":1765960757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的改良型安卡拉痘苗病毒猴痘减毒活疫苗获得国家药品监督管理局药物临床试验申请受理通知书。公司的改良型安卡拉痘苗病毒猴痘减毒活疫苗采用减毒活疫苗技术路线，利用改良型安卡拉痘苗病毒Ankara株进行疫苗生产，Ankara株无法在人体细胞中有效复制，不会在身体中扩散或造成继发传播，安全性较高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：改良型安卡拉痘苗病毒(MVA)猴痘减毒活疫苗临床试验申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064131003.USD","LU2580892862.HKD","BK0046","BK0196","300122","LU1064130708.USD","LU1328615791.USD","BK0077","BK0188","BK0239","LU2580892789.USD"],"gpt_icon":0},{"id":"2590600445","title":"12月11日智飞生物创60日新低，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590600445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590600445?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:37","pubTimestamp":1765438643,"startTime":"0","endTime":"0","summary":"证券之星消息，12月11日智飞生物创60日新低，收盘报19.38元，当日跌2.22%，换手率0.99%，成交量13.98万手，成交额2.73亿元。重仓智飞生物的前十大公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共15家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4034，较上一交易日上涨0.52%，近一年下跌0.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","LU1064131003.USD","BK0196","LU2580892789.USD","BK0046","BK0188","161726","399441","300122"],"gpt_icon":0},{"id":"2588200248","title":"12月4日智飞生物现1笔大宗交易 机构净买入399.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588200248","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588200248?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:58","pubTimestamp":1764838701,"startTime":"0","endTime":"0","summary":"证券之星消息，12月4日智飞生物发生大宗交易，交易数据如下：大宗交易成交价格19.96元，成交20万股，成交金额399.2万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交2000.0手。该股近期无解禁股上市。截至2025年12月4日收盘，智飞生物(300122)报收于19.96元，下跌0.25%，换手率0.81%，成交量11.52万手，成交额2.29亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400025509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1328615791.USD","LU2580892789.USD","LU1064130708.USD","BK0188","300122","BK0077","LU2580892862.HKD","BK0196","LU2148510915.USD","LU1064131003.USD","BK0046"],"gpt_icon":0},{"id":"2586207619","title":"智飞生物：截至2025年11月20日股东人数为130,074","url":"https://stock-news.laohu8.com/highlight/detail?id=2586207619","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586207619?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:57","pubTimestamp":1764320229,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)11月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司截至11月20日的股东人数是多少，谢谢智飞生物回复：您好，截至2025年11月20日，公司普通股股东人数为130,074，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800023938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU1064130708.USD","BK0188","LU2580892789.USD","BK0046","BK0239","BK0077","LU1064131003.USD","300122","BK0196","LU2148510915.USD","LU1328615791.USD"],"gpt_icon":0},{"id":"2584200182","title":"智飞生物（300122）披露重组带状疱疹ZFA01佐剂疫苗临床试验申请获受理，11月20日股价上涨0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584200182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584200182?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:43","pubTimestamp":1763631801,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，智飞生物报收于20.94元，较前一交易日上涨0.48%，最新总市值为501.26亿元。该股当日开盘21.36元，最高21.77元，最低20.92元，成交额达6.67亿元，换手率为2.21%。近日，智飞生物发布公告称，公司全资子公司安徽智飞龙科马生物制药有限公司研发的重组带状疱疹ZFA01佐剂疫苗临床试验申请已获国家药品监督管理局受理，受理号为CXSL2500978。目前该事项对公司近期业绩无重大影响，后续临床试验进度及上市存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000026531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0046","300122","LU1328615791.USD","BK0188","LU1064131003.USD","LU2148510915.USD","BK0196","LU2580892862.HKD","BK0239","LU1064130708.USD","LU2580892789.USD","BK0077"],"gpt_icon":0},{"id":"2584494914","title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2584494914","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584494914?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:37","pubTimestamp":1763545060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简称“智飞龙科马”)研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交的方案开展临床试验。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：重组带状疱疹ZFA01佐剂疫苗(CHO细胞)临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2580892789.USD","159646","BK0046","BK0188","BK0239","LU2580892862.HKD","LU1328615791.USD","BK0196","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0077","300122"],"gpt_icon":0},{"id":"2584914686","title":"智飞生物（300122）披露2025年第二次临时股东会决议公告，11月19日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584914686","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584914686?lang=zh_cn&edition=full","pubTime":"2025-11-19 17:27","pubTimestamp":1763544451,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，智飞生物报收于20.84元，较前一交易日下跌0.95%，最新总市值为498.87亿元。该股当日开盘21.05元，最高21.16元，最低20.73元，成交额达3.05亿元，换手率为1.03%。近日，重庆智飞生物制品股份有限公司发布2025年第二次临时股东会决议公告。本次会议采取现场与网络投票相结合的方式进行，出席股东共计743人，代表股份占公司有表决权股份总数的56.4371%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900027740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD","BK0196","BK0077","LU2580892789.USD","LU2148510915.USD","BK0239","LU1328615791.USD","BK0046","BK0188"],"gpt_icon":0},{"id":"2584660724","title":"股市必读：智飞生物(300122)股东户数13.31万户，较上期增加1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584660724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584660724?lang=zh_cn&edition=full","pubTime":"2025-11-17 01:20","pubTimestamp":1763313624,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，智飞生物报收于21.52元，下跌0.78%，换手率1.91%，成交量27.02万手，成交额5.88亿元。来自股本股东变化：截至11月10日股东户数增至13.31万户，户均持股数量下降至1.8万股，表明筹码略有分散。股本股东变化股东户数变动近日智飞生物披露，截至2025年11月10日公司股东户数为13.31万户，较9月30日增加1562.0户，增幅为1.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0077","LU2148510915.USD","LU1328615791.USD","BK0046","LU2580892789.USD","LU1064131003.USD","BK0196","BK0188","BK0239","LU2580892862.HKD","LU1064130708.USD"],"gpt_icon":0},{"id":"2583573326","title":"智飞生物：四价流感疫苗已获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573326","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583573326?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:18","pubTimestamp":1763108291,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物11月14日在投资者关系平台上答复投资者关心的问题。23年4月董秘在互动易回复是四价流感疫苗已完成临床试验，时隔两年多了，目前这款疫苗上市了吗？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400024995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","BK0188","LU1064130708.USD","BK0046","300122","LU2580892862.HKD","LU2148510915.USD","BK0196","BK0239","BK0077","LU1328615791.USD","LU1064131003.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768414930219,"stockEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0487},{"period":"3month","weight":-0.0263},{"period":"6month","weight":-0.0162},{"period":"1year","weight":-0.2086},{"period":"ytd","weight":0.0615}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"124518人(较上一季度减少2.69%)","perCapita":"11358股","listingDate":"2010-09-28","address":"重庆市江北区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是预防流脑疫苗、宫颈癌疫苗、肺炎疫苗、流感疫苗、轮状病疫苗。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}